Carver Kyle 4

What Happened

• Kyle Carver, Chief Financial Officer of Evommune, received a grant of 98,946 shares classified as a derivative award on 2026-04-16. The filing lists an acquisition price of $0 and reports the transaction as an award/grant (code A). This is a compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-17.
• Security: 98,946 shares (derivative award); price per share listed: $0.00; total reported value: $0.
• Transaction type: Award/Grant (derivative), code A.
• Vesting: Footnote states 1/4 vests on the first anniversary of the grant, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.
• Shares owned after transaction: not specified in the filing.
• No indication of immediate exercise or sale; not reported under a 10b5-1 plan or as a tax-withholding event.

Context

• This grant is typical executive compensation designed to vest over time; as a derivative award it does not represent an immediate inflow or outflow of market shares. Such awards align executive incentives with long-term performance but are not the same as an insider buying shares on the open market.